News | May 20, 2023
Abbott India posts Q4FY23 PAT at Rs. 231.42 Cr
The company has reported total income of Rs. 1392.72 crores during the period ended March 31, 2023
The company has reported total income of Rs. 1392.72 crores during the period ended March 31, 2023
The company has reported total income of Rs. 2971.27 crores during the period ended March 31, 2023
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
Venlafaxine HCl extended-release capsules are indicated for the treatment of: Major Depressive Disorder
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
Testing supporting allergy diagnosis now accessible to more people in more communities
These initiatives aim to improve access to healthcare for rare disease patients
The company has reported total income of Rs. 580.81 crores during the period ended March 31, 2023
Gland Pharma has reported total income of Rs. 823.95 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
